Enbrel ruling lifts Amgen shares

A decision by the U.S. District Court for the District of New Jersey late Friday removed a key overhang on Amgen shares when it upheld two Enbrel patents at stake in a suit against Sandoz.

Shares of Amgen Inc. (NASDAQ:AMGN) spiked in the day’s final minutes of trading as the decision was announced, lifting the stock $11.02 to $196.25...